4147 Stock Overview A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
TaiMed Biologics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for TaiMed Biologics Historical stock prices Current Share Price NT$83.40 52 Week High NT$116.50 52 Week Low NT$66.60 Beta 0.45 1 Month Change -1.88% 3 Month Change 3.99% 1 Year Change 1.21% 3 Year Change 17.63% 5 Year Change -15.84% Change since IPO 300.96%
Recent News & Updates
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 18
Taimed Biologics Inc. Receives Patent Approval from China for Improving the Pharmacokinetic Performance of Tmb-365 Using Histidine Modification Technology Oct 27
No longer forecast to breakeven Oct 22
Price target increased by 17% to NT$152 Aug 28
Second quarter 2024 earnings: Revenues exceed analyst expectations Aug 17
TaiMed Biologics Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 31 See more updates
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 18
Taimed Biologics Inc. Receives Patent Approval from China for Improving the Pharmacokinetic Performance of Tmb-365 Using Histidine Modification Technology Oct 27
No longer forecast to breakeven Oct 22
Price target increased by 17% to NT$152 Aug 28
Second quarter 2024 earnings: Revenues exceed analyst expectations Aug 17
TaiMed Biologics Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 31
TaiMed Biologics Inc. Receives Patent Approval from the US PTO for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology Jul 19
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 18
TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy May 11 TaiMed Biologics Inc. to Report Q1, 2024 Results on May 13, 2024 May 05
New minor risk - Shareholder dilution Apr 30
Forecast breakeven date moved forward to 2024 Apr 22
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 22
TaiMed Biologics Inc., Annual General Meeting, May 28, 2024 Mar 08
Forecast breakeven date moved forward to 2024 Mar 03
Consensus revenue estimates decrease by 25% Feb 28
No longer forecast to breakeven Feb 27
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology Feb 22
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection Dec 22
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo Dec 14
TaiMed Biologics Inc. has filed a Follow-on Equity Offering. Dec 09 TaiMed Biologics Inc. has filed a Follow-on Equity Offering. Dec 08
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study Oct 14
No longer forecast to breakeven Oct 07
No longer forecast to breakeven Sep 29
New minor risk - Profitability Sep 19
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution Sep 07
Forecast to breakeven in 2024 Sep 07
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 13
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy Jun 30
Consensus revenue estimates decrease by 56%, EPS upgraded May 17
Consensus revenue estimates decrease by 29%, EPS upgraded Apr 13
Price target increased by 31% to NT$133 Mar 22
Forecast to breakeven in 2024 Jan 25
Less than half of directors are independent Nov 16
Consensus forecasts updated Sep 26
Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint Aug 19
TaiMed Biologics Inc. Announces First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy Jul 30
TaiMed Biologics Inc. Approves Board Appointments Jun 01
TaiMed Biologics Inc. Receives Official Approval Letter from US FDA May 27
First quarter 2022 earnings: EPS exceeds analyst expectations May 17
Consensus revenue estimates fall by 48% May 10
Forecast breakeven date pushed back to 2023 May 09
TaiMed Biologics Inc. Announces Enrollment of Phase III Clinical Study is Complete for Trogarzo Intramuscular Injection (IM) Apr 28
Price target increased to NT$109 Apr 27
Less than half of directors are independent Apr 27
Forecast breakeven date pushed back to 2023 Apr 14
TaiMed Biologics Inc. Announces Change of CEO Apr 12
Taimed Biologics Inc. Announces FDA Approves 1b/2a Clinical Studying Two Monoclonal Antibody Apr 03
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 03
Price target increased to NT$109 Mar 15
TaiMed Biologics Inc. Submits Initial Safety and Efficacy Results of the Phase I Clinical Trial of Tmb-365 to the US Food and Drug Administration Mar 06
TaiMed Biologics Inc. Announces US FDA Approves Supplemental BLA Filing for the Addition of Samsung Biologics in Korea for Commercial Manufacturing of Trogarzo Feb 26
Taimed Biologics Inc. Announces the Presentation of Positive Results from Trogarzo IV Push Administration Study Feb 17
Forecast breakeven date pushed back to 2023 Dec 15
Third quarter 2021 earnings released: NT$0.31 loss per share (vs NT$0.18 loss in 3Q 2020) Nov 15
Second quarter 2021 earnings released: NT$0.39 loss per share (vs NT$0.12 profit in 2Q 2020) Aug 15
First quarter 2021 earnings released: EPS NT$0.02 (vs NT$0.30 loss in 1Q 2020) May 16
TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook Apr 20
Full year 2020 earnings released: NT$0.73 loss per share (vs NT$2.30 loss in FY 2019) Mar 27
TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18% Mar 16
TaiMed Biologics Inc., Annual General Meeting, May 31, 2021 Mar 11
TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years. Feb 09
New 90-day low: NT$78.60 Jan 15
Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven Jan 05
New 90-day low: NT$85.90 Dec 05
TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry? Dec 01
Revenue and earnings miss expectations Nov 15
Third quarter 2020 earnings released: NT$0.18 loss per share Nov 15
New 90-day low: NT$86.20 Oct 29
Price target raised to NT$143 Aug 31
New 90-day high - NT$112 Aug 26
Price target raised to NT$125 Aug 26
First half earnings released Aug 14 Shareholder Returns 4147 TW Biotechs TW Market 7D 0.6% 3.1% 0.5% 1Y 1.2% 2.5% 27.8%
See full shareholder returns
Return vs Industry: 4147 underperformed the TW Biotechs industry which returned 2.5% over the past year.
Return vs Market: 4147 underperformed the TW Market which returned 27.8% over the past year.
Price Volatility Is 4147's price volatile compared to industry and market? 4147 volatility 4147 Average Weekly Movement 4.3% Biotechs Industry Average Movement 4.5% Market Average Movement 4.4% 10% most volatile stocks in TW Market 7.8% 10% least volatile stocks in TW Market 2.1%
Stable Share Price: 4147 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4147's weekly volatility (4%) has been stable over the past year.
About the Company TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody.
Show more TaiMed Biologics Inc. Fundamentals Summary How do TaiMed Biologics's earnings and revenue compare to its market cap? 4147 fundamental statistics Market cap NT$22.64b Earnings (TTM ) -NT$141.64m Revenue (TTM ) NT$622.61m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4147 income statement (TTM ) Revenue NT$622.61m Cost of Revenue NT$351.99m Gross Profit NT$270.63m Other Expenses NT$412.27m Earnings -NT$141.64m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.52 Gross Margin 43.47% Net Profit Margin -22.75% Debt/Equity Ratio 12.1%
How did 4147 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 08:34 End of Day Share Price 2024/12/25 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources TaiMed Biologics Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yenya Kuo Capital Securities Corporation Jianzheng Wu Capital Securities Corporation Chu Wang Citigroup Inc
Show 7 more analysts 
